Mesa Laboratories (MLAB) CAO Elizabeth Sells $40K of Stock
Crennen Lyndsey Elizabeth, the CAO of Mesa Laboratories, sold 442 shares on June 22, 2026, valued at about $39,559.
Reviewed by automated data checks against the source filing. How we make and check alerts
Crennen Lyndsey Elizabeth, CAO at Mesa Laboratories, Inc. ($MLAB), sold 442 shares at an average price of $89.50, worth about $39,559, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $MLAB is up 6.8% after 1 week, up 5.7% after 1 month and up 31.5% to date (from the $93.11 close on Jun 22, 2026).
MLAB
Mesa Laboratories, Inc.
Key Points
- Crennen Lyndsey Elizabeth sold 442 shares of Mesa Laboratories at a price of $89.50 each, totaling about $39,559.
- The stock is currently trading at $91.97, down from a previous close of $126.54.
- Mesa Laboratories has a market cap of about $738 million and a P/E ratio of 155.14.
Get $MLAB trade alerts by text
We text you when insiders, Congress or big funds trade $MLAB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Mesa Laboratories, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Mesa Laboratories, Inc.
Crennen Lyndsey Elizabeth, the Chief Administrative Officer (CAO) of Mesa Laboratories, Inc. (MLAB), sold 442 shares on June 22, 2026. The shares were sold at a price of $89.50 each, bringing the total transaction value to approximately $39,559. This sale comes shortly after Elizabeth purchased 263 shares for about $25,011 on June 18, 2026.
How Mesa Laboratories, Inc. Stock Has Traded
Currently, Mesa Laboratories' stock trades at $91.97, significantly lower than its previous close of $126.54. Over the past year, the shares have fluctuated between a low of $63.48 and a high of $132.70. The recent insider selling activity may reflect broader market adjustments, particularly as the stock has seen a notable decline from its peak.
Recent Insider Trades
On June 18, 2026, Elizabeth also sold 125 shares of the company. Additionally, on the same day, Brian Archbold, the Senior Vice President of Operations, bought 3,324 shares for around $316,112.4. Archbold also sold 2,516 shares on June 22, 2026, for a total of $225,182. These transactions show active trading among the company's insiders.
Analysts Set New Price Targets
On August 14, 2026, Wells Fargo maintained an Equal-Weight rating on Mesa Laboratories with a price target of $110. This is an increase from a prior target of $94, indicating some optimism about the stock's potential despite the recent volatility.
What Mesa Laboratories, Inc. Does
Mesa Laboratories, Inc. develops and sells life sciences tools and quality control products. Its offerings include sterilization indicators and systems for protein analysis, serving various industries including healthcare and pharmaceuticals. The recent insider trades suggest active management participation amid changing market conditions.
What’s Next for Mesa Laboratories?
Investors will be watching for the company’s next earnings report scheduled for November 5, 2026. The recent insider transactions highlight ongoing adjustments in the company's leadership and may provide insights into future performance. Remember, the details in this report are based on the latest available data and reflect past positions.
Related Filing Alerts
Source: Crennen Lyndsey Elizabeth's Form 4 filing on $MLAB (Jun 22, 2026). Find the original filing: MLAB Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts